Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Astellas Pharma Global Development, Inc.
Samuel Lederman; Faith D Ottery; Antonio Cano; Nanette Santoro; Marla Shapiro; Petra Stute; Rebecca C Thurston; Marci English; Catherine Franklin; Misun Lee; Genevieve Neal-Perry